Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that FIP1L1::PDGFRA status confers therapeutic sensitivity to Imatinib in patients with Chronic Eosinophilic Leukemia, NOS.
The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with a FIP1L1::PDGFRA rearrangement.
This statement is based on a regulatory approval from the European Medicines Agency:
Glivec is indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR_ rearrangement.